Literature DB >> 24968988

Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach.

Jörg Ruof1, Charalabos-Markos Dintsios2, Friedrich Wilhelm Schwartz3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24968988     DOI： 10.1016/j.jval.2014.05.001

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  5 in total

1.  Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany.

Authors:  Matthias Herpers; Charalabos-Markos Dintsios
Journal:  Eur J Health Econ       Date:  2018-04-25

2.  Determinants of Orphan Drug Prices in Germany.

Authors:  Franziska Worm; Charalabos-Markos Dintsios
Journal:  Pharmacoeconomics       Date:  2020-04       Impact factor: 4.981

3.  Benefit assessment in Germany: implications for price discounts.

Authors:  Ulrike Theidel; J-Matthias Graf von der Schulenburg
Journal:  Health Econ Rev       Date:  2016-08-02

4.  Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree.

Authors:  C M Dintsios; F Worm; J Ruof; M Herpers
Journal:  Health Econ Rev       Date:  2019-12-17

5.  How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?

Authors:  Charalabos-Markos Dintsios; Nadja Chernyak
Journal:  Appl Health Econ Health Policy       Date:  2021-12-29       Impact factor: 3.686
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.